TITLE

Impact of malignant stem cell burden on therapy outcome in newly diagnosed chronic myeloid leukemia patients

AUTHOR(S)
Mustjoki, S; Richter, J; Barbany, G; Ehrencrona, H; Fioretos, T; Gedde-Dahl, T; Gjertsen, B T; Hovland, R; Hernesniemi, S; Josefsen, D; Koskenvesa, P; Dybedal, I; Markevärn, B; Olofsson, T; Olsson-Strömberg, U; Rapakko, K; Thunberg, S; Stenke, L; Simonsson, B; Porkka, K
PUB. DATE
July 2013
SOURCE
Leukemia (08876924);Jul2013, Vol. 27 Issue 7, p1520
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
Chronic myeloid leukemia (CML) stem cells appear resistant to tyrosine kinase inhibitors (TKIs) in vitro, but their impact and drug sensitivity in vivo has not been systematically assessed. We prospectively analyzed the proportion of Philadelphia chromosome-positive leukemic stem cells (LSCs, Ph+CD34+CD38−) and progenitor cells (LPCs, Ph+CD34+CD38+) from 46 newly diagnosed CML patients both at the diagnosis and during imatinib or dasatinib therapy (ClinicalTrials.gov NCT00852566). At diagnosis, the proportion of LSCs varied markedly (1-100%) between individual patients with a significantly lower median value as compared with LPCs (79% vs 96%, respectively, P=0.0001). The LSC burden correlated with leukocyte count, spleen size, hemoglobin and blast percentage. A low initial LSC percentage was associated with less therapy-related hematological toxicity and superior cytogenetic and molecular responses. After initiation of TKI therapy, the LPCs and LSCs rapidly decreased in both therapy groups, but at 3 months time point the median LPC level was significantly lower in dasatinib group compared with imatinib patients (0.05% vs 0.68%, P=0.032). These data detail for the first time the prognostic significance of the LSC burden at diagnosis and show that in contrast to in vitro data, TKI therapy rapidly eradicates the majority of LSCs in patients.
ACCESSION #
88937539

 

Related Articles

  • A population study of imatinib in chronic myeloid leukaemia demonstrates lower efficacy than in clinical trials. Lucas, C. M.; Wang, L.; Austin, G. M.; Knight, K.; Watmough, S. J.; Shwe, K. H.; Dasgupta, R.; Butt, Nauman M.; Galvani, D.; Hoyle, C. F.; Seale, J. R. C.; Clark, R. E. // Leukemia (08876924);Oct2008, Vol. 22 Issue 10, p1963 

    The article discusses the significance of imatinib, a tyrosine kinase inihibitor to the patients with chronic myeloid leukaemia (CML). It says that imatinib has become the treatment of choice for newly diagnosed patients in chronic phase. Further, imatinib-treated cohort within the International...

  • An update on allogeneic hematopoietic progenitor cell transplantation for myeloproliferative neoplasms in the era of tyrosine kinase inhibitors. Adekola, K; Popat, U; Ciurea, S O // Bone Marrow Transplantation;Nov2014, Vol. 49 Issue 11, p1352 

    Myeloproliferative neoplasms are a category of diseases that have been traditionally amenable to allogeneic hematopoietic progenitor cell transplantation. Current developments in drug therapy have delayed transplantation for more advanced phases of the disease, especially for patients with CML,...

  • Rapid initial decline in BCR-ABL1 is associated with superior responses to second-line nilotinib in patients with chronic-phase chronic myeloid leukemia. Stein, Andrew M.; Martinelli, Giovanni; Hughes, Timothy P.; Müller, Martin C.; Beppu, Lan; Gottardi, Enrico; Branford, Susan; Soverini, Simona; Woodman, Richard C.; Hochhaus, Andreas; Dong-Wook Kim; Saglio, Giuseppe; Radich, Jerald P. // BMC Cancer;2013, Vol. 13 Issue 1, p1 

    Background: We evaluated BCR-ABL1 kinetics in patients treated with nilotinib and analyzed whether a dynamic model of changes in BCR-ABL1 levels over time could be used to predict long-term responses. Methods: Patients from the nilotinib registration trial (CAMN107A2101; registered at...

  • MOLECULAR RESPONSE IN PATIENTS WITH CHRONIC MYELOID LEUKEMIA TREATED WITH IMATINIB - SINGLE CENTRE EXPERIENCE. Pavkovic, Marica; Angelkovic, Rosica; Popova-Simjanovska, Marija; Genadieva-Stavric, Sonja; Cevreska, Lidija; Stojanovic, Aleksandar // Prilozi;2015, Vol. 36 Issue 2, p179 

    Introduction of tyrosine kinase inhibitors (TKI) dramatically improves the treatment and survival of the patients with chronic myeloid leukemia (CML) in the last decade. Imatinib (IM) and other TKI induce larger percentage of complete cytogenetic response (CCyR) and major molecular response...

  • Switching-On Adherence in Chronic Myeloid Leukemia. Leader, Avi; Raanani, Pia // Acta Haematologica;Nov2017, Vol. 138 Issue 3, p138 

    The authors reflect on the clinical challenge in the management of chronic myeloid leukemia (CML) due to patients' nonadherence to tyrosine kinase inhibitors (TKI). They cite the retrospective study by Maeda et al. that suggests that switching medications from imatinib to nilotinib may resolve...

  • Improved Drug Adherence in Patients with Chronic Myeloid Leukemia in the Chronic Phase by Switching to Second-Generation Tyrosine Kinase Inhibitors. Maeda, Yasuhiro; Okamoto, Atsushi; Kawaguchi, Shin-ichiro; Konishi, Akiko; Yamamoto, Kenta; Eguchi, Go; Kanai, Yoshitaka; Yamaguchi, Terufumi // Acta Haematologica;Nov2017, Vol. 138 Issue 3, p140 

    The article discusses the improved drug adherence in patients with chronic myeloid leukemia (CML) by switching to second-generation tyrosine kinase inhibitors (TKI). It compared the drug adherence rates from Imatinib (IM) to TKI nilotinib (NILO). It notes that adherence is a critical factor for...

  • Traitement par inhibiteurs de tyrosine-kinase de 2 génération chez les patients en échec de l'imatinib. Etienne, G. // Oncologie;Oct2012, Vol. 14 Issue 10/11, p589 

    Imatinib (IM) has dramatically improved the prognosis of chronic myeloid leukemia patients. Unfortunately, 30% of the patients will have to discontinue IM first-line treatment because of failure or intolerance. Second-generation tyrosine-kinase inhibitors, for example nilotinib, dasatinib, and...

  • Activation of apoptosis signaling eliminates CD34+ progenitor cells in blast crisis CML independent of response to tyrosine kinase inhibitors. Mak, D H; Wang, R-Y; Schober, W D; Konopleva, M; Cortes, J; Kantarjian, H; Andreeff, M; Carter, B Z // Leukemia (08876924);Apr2012, Vol. 26 Issue 4, p788 

    Despite being highly effective for newly diagnosed chronic myeloid leukemia (CML), imatinib not only is inactive against quiescent CML stem cells, but also has limited activity against blast crisis (BC) CML. The relative activity of Bcr-Abl and the expression levels of antiapoptotic proteins in...

  • European Society of Hematology.  // BioWorld Today;6/9/2009, Vol. 20 Issue 109, p6 

    The article discusses the data reported by ChemGenex Pharmaceuticals Ltd. from 65 patients in its Phase II/III trial of omacetaxine in chronic myeloid leukemia that are resistant to multiple tyrosine kinase inhibitor therapy. An 80% complete hematologic response rate was observed in chronic...

Share

Read the Article

Courtesy of THE LIBRARY OF VIRGINIA

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics